An interventional study of The MybYte tool, a digital personalised nutrition tool for adolescents undergoing cancer treatment in Paediatric Oncology and Malnutrition in Children, sponsored by KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by KU Leuven · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to develop and test MybYte, a smartphone tool designed to support personalised nutrition for teenagers aged 12-18 undergoing cancer treatment. MybYte will ask short questions about eating, appetite and treatment-related symptoms and provide personalised nutrition advice developed by healthcare professionals. In Phase 1, around 15 teenagers will help co-design and refine the tool through interviews and feedback. In Phase 2, around 15 newly diagnosed teenagers will use MybYte for one week each month over six months, alongside routine assessments of nutrition, body composition, taste, energy needs and quality of life. The study will assess whether MybYte is acceptable, practical and helpful for teenagers receiving cancer treatment.
See uploaded protocol
168 studies on the registry are indexed under Child Nutrition Disorders; 34 are open to participants now.
This study's planned enrollment of 30 is below the median of 400 across 133 interventional studies indexed under Child Nutrition Disorders.
Browse Child Nutrition Disorders studies →KU Leuven is the lead sponsor of 373 studies on the registry; 65 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria Phase 1 and 2:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: The MybYte tool, a digital personalised nutrition tool for adolescents undergoing cancer treatment
In Phase 2, a feasibility and acceptability study, all participants will use MybYte for 7 days each month over 6 months. Using experience sampling methodology (ESM), the tool sends 3-5 brief prompts per day about dietary intake, treatment-related symptoms and side effects, appetite, and taste preferences. Based on their responses, participants receive immediate, targeted nutrition tips. Once a month, researchers will integrate body composition and dietary intake data to provide more personalised nutrition feedback and advice. The tool is primarily a health communication tool.
The MybYte tool
Phase 1: Final version of MybYte, a digital personalised nutrition tool for adolescents undergoing cancer treatment
Time frame: From the time of enrollment into phase 1 until month 8
Feasibility (%)
Phase 2: Feasibility of the MybYte tool determined by engagement (%), recruitment (%), and retention (%)
Time frame: From enrollment into phase 2 until end of month 6
Acceptability (5 point response scale)
Phase 2: Acceptability of the MybYte tool will be determined by questionnaire at month 3 and 6, including a 5 point response scale to the following categories: engagement, functionality, aesthetics, content, relevance, interference, quality, and perceived impact.
Time frame: From enrollment into phase 2 until end of month 6
Adolescent perspectives of nutrition during cancer treatment
Phase 1: Thematic analysis of semi-structured interviews exploring adolescents' lived experiences regarding nutrition, nutritional status, and nutrition communication during cancer treatment
Time frame: From enrollment into phase 1 to end of month one
Fat mass (kg)
Phase 2: Fat mass (kg) measured monthly by the Bodystat Multiscan 5000 bioelectrical impedance spectroscopy
Time frame: From enrollment into phase 2 to the end of month 6
Fat free mass (kg)
Phase 2: Fat free mass (kg) measured monthly by the Bodystat Multiscan 5000 bioelectrical impedance spectroscopy
Time frame: From enrollment into phase 2 until end of month 6
Skeletal muscle mass (kg)
Phase 2: skeletal muscle mass (kg) measured monthly by the Bodystat Multiscan 5000 bioelectrical impedance spectroscopy
Time frame: From the time on enrollment into phase 2 until the end of month 6
Phase angle (degrees)
Phase 2: Phase angle (degrees) measured monthly by the Bodystat Multiscan 5000 bioelectrical impedance spectroscopy
Time frame: From enrollment into phase 2 until the end of month 6
Body mass index (kg/m^2)
Phase 2: Body mass index. weight (kg) and height (m) will be combined to report BMI in kg/m\^2.
Time frame: From enrollment into phase 2 until the end of month 6.
Resting energy metabolism (kcal/day)
Phase 2: Resting energy metabolism (kcal/day) measured monthly via the Bodystat Multiscan 5000 bioelectrical impedance spectroscopy and at diagnosis, month 3, and month 6 using indirect calorimetry.
Time frame: From enrollment into phase 2 to end of month 6.
Generic health- related quality of life (5 point response scale)
Phase 2: Health- related quality of life at diagnosis, months 3, and 6 using the PedsQL 4.0. Items are rated on a 5-point response scale ranging from 0 (never a problem) to 4 (almost always a problem)
Time frame: From enrollment into phase 2 to the end of month 6
Cancer specific health-related quality of life (5 point response scale)
Phase 2: Cancer specific health-related quality of life measured at diagnosis, month 3, and month 6 by the PedsQL 3.0 Cancer Module. Items are rated on a 5-point response scale ranging from 0 (never a problem) to 4 (almost always a problem)
Time frame: From enrollment into phase 2 until the end of month 6
Macronutrient dietary intake (g/day)
Phase 2: Protein, fat, and carbohydrate intake (g/day), measured over 7 days per month for 6 months using the MybYte tool.
Time frame: From enrollment into phase 2 to the end of month 6.
Dietary food group intake (g/day)
Phase 2: Dietary food group intake (g/day), measured over 7 days per month for 6 months using the MybYte tool.
Time frame: From enrollment into phase 2 until the end of month 6
Plan to share: No — Individual participant data will not be shared with other researchers because the study involves a small number of adolescent participants and collects sensitive health-related data, which could increase the risk of participant re-identification. Study findings will be reported in accordance with applicable privacy and data-protection requirements.
Start is estimated for Sep 2026; primary completion for Mar 2029, 30 months later.
Of 83 non-industry interventional studies with no phase under Child Nutrition Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's planned 30 months is above that.
Counting every sponsor, half of 86 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.